...
首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Effects of Kamishoyosan, a Traditional Japanese Medicine, on Menopausal Symptoms: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial
【24h】

Effects of Kamishoyosan, a Traditional Japanese Medicine, on Menopausal Symptoms: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial

机译:卡曼扬素母,一种传统日本医学,对年经症状的影响:随机,安慰剂控制,双盲临床试验

获取原文
           

摘要

Objective. Kampo medicine, a traditional Japanese medicine, is widely used in Japan, especially in the field of menopause medicine. However, few studies have shown evidence-based effects. This study aimed to confirm the effects of kamishoyosan on menopausal symptoms with a randomized, placebo-controlled, double-blind clinical trial. Methods. Subjects were randomly allocated to groups that received either kamishoyosan (n?=?101) or a placebo resembling kamishoyosan (n?=?104). The primary outcomes were the change in the number of hot flashes, depression scores, improvements of anxiety, quality of life (QOL), and menopausal symptoms before and 4 and 8 weeks after initiation of treatment with the study drug. The secondary outcome was drug safety. Results. After 8 weeks, the number of hot flashes decreased after treatment in both groups, but there was no significant difference between the two groups. The changes in SDS scores showed the same results. Moreover, no significant differences were observed between the two groups in assessments with the STAI, SF-36, and JSOG menopausal index. No serious adverse effect was reported. Conclusions. This first placebo-controlled double-blind randomized trial with kamishoyosan demonstrated that it was safe and had some effects on climacteric symptoms, but not significant compared with placebo. Some problems, such as placebo effects, in the study of Kampo therapy for menopausal symptoms, were revealed. This trial is registered with the trial registration number. UMIN 000006042.
机译:客观的。康沃医学是一种传统的日本医学,广泛用于日本,特别是在更年期医学领域。然而,很少有研究表明基于证据的效果。本研究旨在通过随机,安慰剂对照,双盲临床试验确认Kamishoyosan对更年期症状的影响。方法。受试者被随机分配给接受Kamishoyosan(N?= 101)或类似于Kamishoyosan的安慰剂(n?= 104)的分组。主要结果是热闪光,抑郁症分数,焦虑,生活质量(QOL质量(QOL)的变化以及在与研究药物治疗开始后4和8周的更年期症状。二次结果是药物安全性。结果。 8周后,两组治疗后,热闪光的数量降低,但两组之间没有显着差异。 SDS分数的变化显示了相同的结果。此外,两组在评估中没有显着差异,在梯级,SF-36和JSOG绝经指数中的评估中。没有报道任何严重的不良反应。结论。与Kamishoyosan的第一次安慰剂受控的双盲随机试验表明,它是安全的,对更年期的症状有一些影响,但与安慰剂相比没有显着。揭示了一些问题,例如安慰剂效应,促进了康沃治疗对更年期症状的康沃症状。此试验在试验登记号码中注册。 umin 000006042。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号